Diabetes drug raises fears of another Vioxx

updated 6:19 p.m. ET May 22, 2007

First the painkiller Vioxx; now the diabetes drug Avandia. Another big drug safety issue has consumer groups, doctors and congressmen calling for an overhaul of the U.S. Food and Drug Administration.

On Monday, a medical journal published an analysis suggesting that Avandia raised the risk of heart attacks and possibly deaths. More than 6 million people worldwide have taken the drug to control blood sugar since it came on the market eight years ago, and about 1 million Americans use it now.

Cases like this will continue “until we are able to get a better system of drug approval and surveillance,” said Dr. Jerry Avorn, a Harvard Medical School professor and author who has criticized the FDA for not watching more closely for problems with drugs it has approved.

The consumer group Public Citizen said the FDA has failed to require Avandia’s maker to adequately warn about the dangers of the drug. And Consumers Union called on the agency to make results of all consumer drug testing public “so doctors, researchers and patients can more quickly know about a drug’s possible risks.”

Pooled results of dozens of studies on nearly 28,000 people revealed a 43 percent higher risk of heart attack for those taking Avandia compared to people taking other diabetes drugs or no diabetes medication, according to the analysis published online Monday by the New England Journal of Medicine.

Particularly hazardous link
The findings are frightening because two-thirds of the people with Type 2 diabetes, the most common form, die of heart problems, so a drug that boosts this possibility is especially hazardous for them.

NBC video Diabetes drug hikes heart attack risk May 21: New research shows that a widely prescribed diabetes drug, Avandia, increases heart attack risk by 43 percent. Nightly News

Still, the actual risks to any single patient appear small. Diabetics should talk to their doctors before stopping any medication, said a statement issued by the American Diabetes Association and two groups of heart doctors.

Avandia’s maker, British-based GlaxoSmithKline PLC, disputed the results of the analysis but acknowledged that its own similar review found a 30 percent increased risk — information it gave last August and possibly even earlier to the Food and Drug Administration. But the company said that more rigorous studies did not confirm excess risk.

FDA officials issued a safety alert on Monday and said they likely would convene an advisory panel, but planned no immediate changes to the current side effect warnings on the drug’s packaging.

Legislators announce hearing
Several members of Congress expressed alarm. Rep. Henry Waxman, D-Calif., chairman of the House Committee on Oversight and Government Reform, announced a hearing for June 6 on FDA’s role. On the Senate floor, Charles Grassley, R-Iowa, criticized the agency for not acting more swiftly.

“Do we have another Vioxx on our hands with Avandia? I am not sure, but I intend to find out,” he said, referring to the blockbuster arthritis drug withdrawn in 2004 because of safety problems. “Tens of millions of prescriptions have been written for Avandia, and Medicare and Medicaid have paid hundreds of millions of dollars for this drug.”

Avandia is used to treat Type 2 diabetes, which is linked to obesity and afflicts 18 million Americans and 200 million people worldwide. This form of diabetes occurs when the body does not make enough insulin or cannot effectively use what it manages to produce.

Avandia, or rosiglitazone, helps sensitize the body to insulin and was considered a breakthrough medication for blood-sugar control. It also is combined with metformin and sold as Avandamet. Only one other drug like it — pioglitazone, sold as Actos and Actoplus Met by Takeda Pharmaceuticals — is sold in the United States.

Avandia had total U.S. sales of $2.2 billion in 2006, slightly trailing $2.6 billion for Actos, according to IMS Health, a healthcare information company. About 13 million Avandia prescriptions were filled in the U.S. last year. A one-month supply of Avandia sells for between $90 and $170.

Shadow cast on potential Alzheimer's therapy
GlaxoSmithKline also has been testing Avandia to try to prevent diabetes in those at high risk of it, and, in separate studies, to prevent Alzheimer’s disease.

However, the new analysis casts a pall on its prospects for prevention as well as treatment, many specialists said. The study was led by Dr. Steven Nissen and statistician Kathy Wolski at the Cleveland Clinic. Nissen accepts no personal fees for consulting for any drug makers.

While the analysis doesn’t spell out the actual the rate of heart attacks among Avandia users, the 43 percent excess risk is in line with what a similar analysis found for lower doses of Vioxx use, Nissen said. Another context for that number: Heart attack risks are lowered about 25 percent by cholesterol-reducing statin drugs — ample reason to prescribe them.

The Avandia studies Nissen analyzed were not designed to look for heart risks and many of them were so short — some only 24 weeks — that risks may only appear over the longer term, he said.

Dr. David Nathan, chief of diabetes care at Massachusetts General Hospital, agreed.

MORE FROM DIABETES

Diabetes Section Front

New shot aims to head off Type 1 diabetes Dogs being trained to sniff out diabetes Insulin maker warns about stolen medicine Heart drugs as helpful as surgery for diabetics Drugmakers vie for lucrative diabetes market Diabetes soars in Asia — especially in the young Supreme Court nominee has Type 1 diabetes FDA OKs drug that treats diabetes via the brain Drug may help prevent or delay diabetes Beating diabetes: Some do, but are they cured? Diabetes Section Front   Add Diabetes headlines to your news reader: